💥Should Long-term Investors Buy Unitedhealth?

In partnership with

Hello Fellow Investors!

UnitedHealth (NYSE: UNH) has taken a beating—its stock has cratered over 40%, making it the worst performer in the Dow this year. For a company that was once a fortress of steady returns, the collapse has stunned Wall Street.

News of leadership changes, slowing profit growth, and a string of unsettling headlines have fueled the sell-off. But beneath the chaos, insiders are quietly buying up shares—and that’s often a telling signal for long-term value.

Is this just a temporary storm or a deeper structural crack? For long-term investors, this could be the moment to look closer at what others are running away from.Key Points:

• UnitedHealth’s stock has plunged more than 40%, hitting levels not seen in half a decade.

• Concerns over slowing earnings, executive turnover, and negative headlines have shaken investor confidence.

• Despite the turmoil, insider buying and steady fundamentals hint at a potential rebound for patient investors.

What’s Fueling the Fire Behind UnitedHealth’s Meltdown

UnitedHealth’s fall from grace has been rapid and dramatic, triggered by a wave of disappointing earnings, executive shakeups, and regulatory headwinds.

In Q1, the company slashed its EPS guidance from $28.65 down to as low as $24.65, citing higher-than-expected costs in its Medicare Advantage business and reimbursement issues in its Optum Health division.

The situation worsened when CEO Andrew Witty abruptly resigned, adding uncertainty to an already rattled investor base.

Just as the dust began to settle, a DOJ investigation into Medicare billing surfaced—sending more shockwaves through the market.

While management called the claims “deeply irresponsible,” the damage to sentiment was already done.

In a matter of weeks, UnitedHealth went from being one of the most stable blue-chip health stocks to a high-profile cautionary tale.

Valuation Freefall or Once-in-a-Decade Discount?

After the storm, UnitedHealth’s stock is now trading near $300—a level not seen since 2019.

Once priced at a premium compared to competitors like Cigna and Humana, its valuation has collapsed to the mid-range of the sector.

Just weeks ago, it carried a forward P/E multiple nearly double today’s figure. For value-focused investors, this dramatic shift is exactly the kind of setup that triggers opportunity alarms.

A steep decline in valuation paired with fundamentally resilient business lines could make this a textbook “overreaction” by the market. T

he question is whether UnitedHealth’s long-term moat in healthcare is strong enough to withstand short-term turbulence—and whether this discount will last long.

Why Some Believe This Is the Smart Money’s Moment

Despite the swirl of negative headlines, a clear signal has emerged: insiders are buying the dip in size.

New CEO Stephen Hemsley recently scooped up $25 million worth of stock, followed by $6.6 million in additional insider purchases.

This kind of conviction from leadership isn’t just symbolic—it’s strategic. Management believes the business will return to growth next year, and these insider bets suggest they’re confident the worst is behind them.

For long-term investors, this moment could be a gift wrapped in panic.

With much of the bad news already reflected in the share price, this may be a rare window to enter a dominant healthcare giant at a steep discount before the market catches up.

Strengths

• Market Leadership: UnitedHealth remains the largest health insurer in the U.S., with deep institutional relationships and operational scale.

• Diverse Revenue Streams: With insurance, pharmacy benefits, and healthcare services under one roof, the company enjoys strong vertical integration.

• Insider Confidence: Heavy insider buying signals internal belief in the company's rebound and long-term profitability.

Weaknesses

• Earnings Uncertainty: Lowered EPS guidance and cost pressures in Medicare plans raise concerns about near-term profitability.

• Leadership Instability: The sudden resignation of the CEO has created a leadership void at a crucial time.

• Regulatory Pressure: Ongoing investigations and government scrutiny could lead to reputational damage or fines.

Potential

• Rebound from Oversold Levels: The stock’s sharp drop could set the stage for a strong recovery if fundamentals stabilize.

• Return to Growth in 2026: Management expects performance to normalize and improve next year, presenting upside potential.

• Repricing Opportunity: If sentiment shifts, UnitedHealth’s valuation could quickly revert to historical norms, driving capital gains.

Conclusion

When a best-in-class company trades like it's broken, seasoned investors know to lean in, not walk away.

UnitedHealth’s challenges are real, but so is its track record of resilience and reinvention. With leadership betting their own money and future growth on the table, now may be the time to act—not after the rebound has already begun.

Sometimes the best investments come wrapped in controversy.

^{Disclaimer: The content provided on this blog is for educational and informational purposes only and is not intended as financial, investment, tax, or legal advice. Investing in the stock market involves risks, including the loss of principal. The views, thoughts, and opinions expressed in this blog are solely those of the author and do not reflect the views of any company, organization, or other group. Readers are encouraged to perform their own research and due diligence before making any financial decisions and actions based on the content. Neither the author nor the publisher is liable for any losses or damages arising from the use of the advice or information contained herein.}